Difference in drug cost between private and public drug plans in Quebec, Canada.


Journal

BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677

Informations de publication

Date de publication:
14 Feb 2022
Historique:
received: 02 06 2021
accepted: 03 02 2022
entrez: 15 2 2022
pubmed: 16 2 2022
medline: 17 2 2022
Statut: epublish

Résumé

We expect a difference in drug cost between private drug plans and the Public Drug Plan (PDP) because the dispensing fee is fixed and regulated by the PDP for publicly insured patients, whereas it is determined freely by the pharmacy owner for privately insured patients. This study compared the drug cost of Quebec residents covered by private drug plans with those covered by PDP. We used a sample of prescriptions filled between 1 January 2015 and 23 May 2019 selected from reMed, a database of Quebecers' drug claims. We created strata of prescriptions filled by privately insured patients and matched them with strata of prescriptions filled by publicly insured patients based on the Drug Identification Number, quantity dispensed, number of days of supply, pharmacy identifier, and a date corresponding to the publication of List of Medications of Régie de l'Assurance Maladie du Québec. The differences in drug cost between private plans and the PDP were analyzed with linear regression models using prescription strata as the unit of analysis. Based on 38 896 prescription strata, we observed that privately insured patients payed $9·35 (95% confidence interval [CI]: 5·58; 13·01) more on average per drug prescription than publicly insured patients, representing a difference of 17·6%. This study showed that, on average, drug cost is substantially higher for privately insured Quebecers. Knowing that adherence to treatment is affected by drug cost, these results will help public health authorities to make informed decisions about drug policies.

Sections du résumé

BACKGROUND BACKGROUND
We expect a difference in drug cost between private drug plans and the Public Drug Plan (PDP) because the dispensing fee is fixed and regulated by the PDP for publicly insured patients, whereas it is determined freely by the pharmacy owner for privately insured patients. This study compared the drug cost of Quebec residents covered by private drug plans with those covered by PDP.
METHODS METHODS
We used a sample of prescriptions filled between 1 January 2015 and 23 May 2019 selected from reMed, a database of Quebecers' drug claims. We created strata of prescriptions filled by privately insured patients and matched them with strata of prescriptions filled by publicly insured patients based on the Drug Identification Number, quantity dispensed, number of days of supply, pharmacy identifier, and a date corresponding to the publication of List of Medications of Régie de l'Assurance Maladie du Québec. The differences in drug cost between private plans and the PDP were analyzed with linear regression models using prescription strata as the unit of analysis.
RESULTS RESULTS
Based on 38 896 prescription strata, we observed that privately insured patients payed $9·35 (95% confidence interval [CI]: 5·58; 13·01) more on average per drug prescription than publicly insured patients, representing a difference of 17·6%.
CONCLUSIONS CONCLUSIONS
This study showed that, on average, drug cost is substantially higher for privately insured Quebecers. Knowing that adherence to treatment is affected by drug cost, these results will help public health authorities to make informed decisions about drug policies.

Identifiants

pubmed: 35164750
doi: 10.1186/s12913-022-07611-4
pii: 10.1186/s12913-022-07611-4
pmc: PMC8845277
doi:

Substances chimiques

Pharmaceutical Preparations 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

200

Informations de copyright

© 2022. The Author(s).

Références

Health Aff (Millwood). 2001 Mar-Apr;20(2):74-85
pubmed: 11260961
Can J Cardiol. 2014 May;30(5):560-7
pubmed: 24613090
Health Aff (Millwood). 2001 Jan-Feb;20(1):276-86
pubmed: 11194852
Health Policy. 2005 Feb;71(2):181-93
pubmed: 15607380
J Nurs Scholarsh. 2003;35(3):207
pubmed: 14562485
J Behav Med. 2005 Feb;28(1):43-51
pubmed: 15887875

Auteurs

Chamoun M (C)

Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada.
Centre Intégré Universitaire de Santé Et de Services, sociaux du Nord-de-l'île-de-Montréal, Montreal, QC, Canada.

Forget A (F)

Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada.
Centre Intégré Universitaire de Santé Et de Services, sociaux du Nord-de-l'île-de-Montréal, Montreal, QC, Canada.

Chabot I (C)

Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada.

Schnitzer M (S)

Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada.

Blais L (B)

Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada. lucie.blais@umontreal.ca.
Centre Intégré Universitaire de Santé Et de Services, sociaux du Nord-de-l'île-de-Montréal, Montreal, QC, Canada. lucie.blais@umontreal.ca.
Endowment Pharmaceutical Chair AstraZeneca in Respiratory Health, Montreal, QC, Canada. lucie.blais@umontreal.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH